Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2024; 84(02): 130-143
DOI: 10.1055/a-2201-2680
GebFra Science
Statement/Stellungnahme

Management von rheumatischen Erkrankungen in Schwangerschaft und Stillzeit

Positionspapier der Arbeitsgemeinschaft für Geburtshilfe und Pränatalmedizin in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. (AGG – Sektion Maternale Erkrankungen in der Schwangerschaft) Article in several languages: English | deutsch
Bettina Kuschel
1   Sektion Geburtshilfe und Perinatologie, Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany
,
Ute Margaretha Schäfer-Graf
2   Perinatalzentrum, Klinik für Gynäkologie und Geburtshilfe, Berlin, Germany
,
Markus Schmidt
3   Gynecology & Obstetrics, Sana Kliniken Duisburg GmbH, Duisburg, Germany
,
Maritta Kühnert
4   Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Gießen und Marburg – Standort Marburg, Marburg, Germany
,
Carsten Hagenbeck
5   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany
,
Klaus Thürmel
6   Abteilung für Nephrologie und Rheumatologie, Klinik Augustinum München, München, Germany
,
for the AGG – Section Maternal Diseases in Pregnancy › Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Zielsetzung Diese Empfehlungen der AGG (Sektion maternale Erkrankungen in der Schwangerschaft) sollen bei maternalen rheumatischen Erkrankungen eine schnelle Orientierung für Beratung und Management in Schwangerschaft und Stillzeit geben.

Methoden Die gängige Literatur, Konsensus- und Positionspapiere, Leitlinien und Empfehlungen anderer Fachgesellschaften wurden durch eine Arbeitsgruppe der Sektion bewertet und nach gemeinsamer Konsensusfindung in diese Empfehlungen gefasst.

Empfehlungen Das Manuskript gibt einen orientierenden Einblick in Physiologie, Pathophysiologie und Definitionen rheumatischer Erkrankungen, die für den Gynäkologen und Geburtshelfer relevant sein können. Die Empfehlungen beziehen sich auf mütterliche, fetale und neonatologische Diagnostik bei Vorliegen maternaler rheumatischer Grunderkrankungen.

Schlüsselwörter

Rheuma - Schwangerschaft - Lupus erythemathodes - Antiphospholipid-Antikörper - Arthritis - Vaskulitis


Publication History

Received: 10 August 2023

Accepted after revision: 23 October 2023

Article published online:
08 February 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Arbuckle MR, McClain MT, Rubertone MV. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533
    CrossrefPubMedSearch in Google Scholar
  • 2 Andreoli L, Bertsias GK, Agmon-Levin N. et al. EULAR recommendations for womenʼs health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76: 476-485
    CrossrefPubMedSearch in Google Scholar
  • 3 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78: 1296-1304
    CrossrefPubMedSearch in Google Scholar
  • 4 Götestam Skorpen C, Hoeltzenbein M, Tincani A. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75: 795-810
    CrossrefPubMedSearch in Google Scholar
  • 5 Sammaritano LR, Bermas BL, Chakravarty EE. et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2020; 72: 529-556
    CrossrefPubMedSearch in Google Scholar
  • 6 Sciascia S, Radin M, Cecchi I. et al. 16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. Lupus 2021; 30: 1314-1326
    CrossrefPubMedSearch in Google Scholar
  • 7 Gordon C, Amissah-Arthur MB, Gayed M. et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology (Oxford) 2018; 57: 14-18
    CrossrefPubMedSearch in Google Scholar
  • 8 Fischer-Betz R, Haase I. [Pregnancy with lupus erythematosus-an update]. Z Rheumatol 2020; 79: 359-366
    CrossrefPubMedSearch in Google Scholar
  • 9 Kwok LW, Tam LS, Zhu T. et al. Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus 2011; 20: 829-836
    CrossrefPubMedSearch in Google Scholar
  • 10 Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 2011; 38: 1012-1016
    CrossrefPubMedSearch in Google Scholar
  • 11 Buyon JP, Kim MY, Guerra MM. et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med 2015; 163: 153-163
    CrossrefPubMedSearch in Google Scholar
  • 12 Buyon JP, Kim MY, Guerra MM. et al. Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol 2017; 12: 940-946
    CrossrefPubMedSearch in Google Scholar
  • 13 Rodrigues BC, Lacerda MI, Ramires de Jesus GR. et al. The impact of different classes of lupus nephritis on maternal and fetal outcomes: a cohort study of 147 pregnancies. Lupus 2019; 28: 492-500
    CrossrefPubMedSearch in Google Scholar
  • 14 Smyth A, Oliveira GH, Lahr BD. et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5: 2060-2068
    CrossrefPubMedSearch in Google Scholar
  • 15 Dong Y, Yuan F, Dai Z. et al. Preeclampsia in systemic lupus erythematosus pregnancy: a systematic review and meta-analysis. Clin Rheumatol 2020; 39: 319-325
    CrossrefPubMedSearch in Google Scholar
  • 16 Bandoli G, Singh N, Strouse J. et al. Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications: A Mediation Analysis of Autoimmune Conditions and Adverse Pregnancy Outcomes. Arthritis Care Res (Hoboken) 2020; 72: 256-264
    CrossrefPubMedSearch in Google Scholar
  • 17 Skorpen CG, Lydersen S, Gilboe IM. et al. Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. Ann Rheum Dis 2018; 77: 264-269
    CrossrefPubMedSearch in Google Scholar
  • 18 Koh JH, Ko HS, Kwok SK. et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus 2015; 24: 210-217
    CrossrefPubMedSearch in Google Scholar
  • 19 Seo MR, Chae J, Kim YM. et al. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus 2019; 28: 722-730
    CrossrefPubMedSearch in Google Scholar
  • 20 Clowse MEB, Eudy AM, Balevic S. et al. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med 2022;
    CrossrefPubMedSearch in Google Scholar
  • 21 Leroux M, Desveaux C, Parcevaux M. et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 2015; 24: 1384-1391
    CrossrefPubMedSearch in Google Scholar
  • 22 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017; 377: 613-622
    CrossrefPubMedSearch in Google Scholar
  • 23 Roberge S, Nicolaides K, Demers S. et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216: 110-120.e6
    CrossrefPubMedSearch in Google Scholar
  • 24 Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013; 30: 260-279
    CrossrefPubMedSearch in Google Scholar
  • 25 Ruiz-Irastorza G, Khamashta MA. Evaluation of systemic lupus erythematosus activity during pregnancy. Lupus 2004; 13: 679-682
    CrossrefPubMedSearch in Google Scholar
  • 26 Yee CS, Khamashta M, Akil M. et al. The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients. Rheumatol Adv Pract 2022; 6: rkac081
    CrossrefPubMedSearch in Google Scholar
  • 27 Lockshin MD, Kim M, Laskin CA. et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311-2318
    CrossrefPubMedSearch in Google Scholar
  • 28 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306
    CrossrefPubMedSearch in Google Scholar
  • 29 Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med 2018; 378: 2010-2021
    CrossrefPubMedSearch in Google Scholar
  • 30 Buyon JP, Winchester RJ, Slade SG. et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 1993; 36: 1263-1273
    CrossrefPubMedSearch in Google Scholar
  • 31 Jaeggi E, Laskin C, Hamilton R. et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010; 55: 2778-2784
    CrossrefPubMedSearch in Google Scholar
  • 32 Brito-Zeron P, Izmirly PM, Ramos-Casals M. et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11: 301-312
    CrossrefPubMedSearch in Google Scholar
  • 33 Brucato A, Cimaz R, Caporali R. et al. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011; 40: 27-41
    CrossrefPubMedSearch in Google Scholar
  • 34 Cuneo BF, Sonesson SE, Levasseur S. et al. Home Monitoring for Fetal Heart Rhythm During Anti-Ro Pregnancies. J Am Coll Cardiol 2018; 72: 1940-1951
    CrossrefPubMedSearch in Google Scholar
  • 35 Friedman DM, Kim MY, Copel JA. et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117: 485-493
    CrossrefPubMedSearch in Google Scholar
  • 36 Izmirly PM, Costedoat-Chalumeau N, Pisoni CN. et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126: 76-82
    CrossrefPubMedSearch in Google Scholar
  • 37 Cimaz R, Spence DL, Hornberger L. et al. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003; 142: 678-683
    CrossrefPubMedSearch in Google Scholar
  • 38 Boros CA, Spence D, Blaser S. et al. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum 2007; 57: 261-266
    CrossrefPubMedSearch in Google Scholar
  • 39 Levy R, Briggs L, Silverman E. et al. Cutaneous sequelae in neonatal lupus: A retrospective cohort study. J Am Acad Dermatol 2020; 83: 440-446
    CrossrefPubMedSearch in Google Scholar
  • 40 Dima A, Jurcut C, Chasset F. et al. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis 2022; 14
    CrossrefPubMedSearch in Google Scholar
  • 41 Izmirly P, Kim M, Friedman DM. et al. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol 2020; 76: 292-302
    CrossrefPubMedSearch in Google Scholar
  • 42 Eudy AM, McDaniel G, Clowse MEB. Pregnancy in rheumatoid arthritis: a retrospective study. Clin Rheumatol 2018; 37: 789-794
    CrossrefPubMedSearch in Google Scholar
  • 43 Ruiz-Irastorza G, Lima F, Alves J. et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996; 35: 133-138
    CrossrefPubMedSearch in Google Scholar
  • 44 Barrett JH, Brennan P, Fiddler M. et al. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 1999; 42: 1219-1227
    CrossrefPubMedSearch in Google Scholar
  • 45 [Anonymous] Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium – RCOG Green-top Guideline No. 37a. 2015. Accessed Decemver 22, 2023 at: https://www.rcog.org.uk/media/qejfhcaj/gtg-37a.pdf
    PubMed
  • 46 Anderson JE, Held N, Wright K. Raynaudʼs phenomenon of the nipple: a treatable cause of painful breastfeeding. Pediatrics 2004; 113: e360-e364
    CrossrefPubMedSearch in Google Scholar
  • 47 Barrett ME, Heller MM, Stone HF. et al. Raynaud phenomenon of the nipple in breastfeeding mothers: an underdiagnosed cause of nipple pain. JAMA Dermatol 2013; 149: 300-306
    CrossrefPubMedSearch in Google Scholar
  • 48 Anderson PO. Drug Treatment of Raynaudʼs Phenomenon of the Nipple. Breastfeed Med 2020; 15: 686-688
    CrossrefPubMedSearch in Google Scholar
  • 49 Jethwa H, Lam S, Smith C. et al. Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis. J Rheumatol 2019; 46: 245-250
    CrossrefPubMedSearch in Google Scholar
  • 50 Huang W, Wu T, Jin T. et al. Maternal and fetal outcomes in pregnant women with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2023; 42: 855-870
    CrossrefPubMedSearch in Google Scholar
  • 51 Eudy AM, McDaniel G, Clowse ME. Pregnancy outcomes, fertility, and family planning in women with psoriatic arthritis. Obstet Med 2020; 13: 70-75
    CrossrefPubMedSearch in Google Scholar
  • 52 Giovannopoulou E, Gkasdaris G, Kapetanakis S. et al. Ankylosing Spondylitis and Pregnancy: A Literature Review. Curr Rheumatol Rev 2017; 13: 162-169
    CrossrefPubMedSearch in Google Scholar
  • 53 Ghalandari N, Kemper E, Crijns IH. et al. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis 2022; 81: 402-405
    CrossrefPubMedSearch in Google Scholar
  • 54 Romanowska-Prochnicka K, Felis-Giemza A, Olesinska M. et al. The Role of TNF-alpha and Anti-TNF-alpha Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci 2021; 22: 2922
    CrossrefPubMedSearch in Google Scholar
  • 55 Nielsen OH, Gubatan JM, Juhl CB. et al. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022; 20: 74-87.e3
    CrossrefPubMedSearch in Google Scholar
  • 56 Tardif ML, Mahone M. Mixed connective tissue disease in pregnancy: A case series and systematic literature review. Obstet Med 2019; 12: 31-37
    CrossrefPubMedSearch in Google Scholar
  • 57 Sims C, Clowse MEB. A comprehensive guide for managing the reproductive health of patients with vasculitis. Nat Rev Rheumatol 2022; 18: 711-723
    CrossrefPubMedSearch in Google Scholar